Cell transplantation therapies for spinal cord injury focusing on bone marrow mesenchymal stem cells: Advances and challenges.

IF 3.6 3区医学 Q3 CELL & TISSUE ENGINEERING

World journal of stem cells Pub Date : 2023-05-26 DOI:10.4252/wjsc.v15.i5.385

Li-Yi Huang, Xin Sun, Hong-Xia Pan, Lu Wang, Cheng-Qi He, Quan Wei

{"title":"Cell transplantation therapies for spinal cord injury focusing on bone marrow mesenchymal stem cells: Advances and challenges.","authors":"Li-Yi Huang, Xin Sun, Hong-Xia Pan, Lu Wang, Cheng-Qi He, Quan Wei","doi":"10.4252/wjsc.v15.i5.385","DOIUrl":null,"url":null,"abstract":"<p><p>Spinal cord injury (SCI) is a devastating condition with complex pathological mechanisms that lead to sensory, motor, and autonomic dysfunction below the site of injury. To date, no effective therapy is available for the treatment of SCI. Recently, bone marrow-derived mesenchymal stem cells (BMMSCs) have been considered to be the most promising source for cellular therapies following SCI. The objective of the present review is to summarize the most recent insights into the cellular and molecular mechanism using BMMSC therapy to treat SCI. In this work, we review the specific mechanism of BMMSCs in SCI repair mainly from the following aspects: Neuroprotection, axon sprouting and/or regeneration, myelin regeneration, inhibitory microenvironments, glial scar formation, immunomodulation, and angiogenesis. Additionally, we summarize the latest evidence on the application of BMMSCs in clinical trials and further discuss the challenges and future directions for stem cell therapy in SCI models.</p>","PeriodicalId":23775,"journal":{"name":"World journal of stem cells","volume":"15 5","pages":"385-399"},"PeriodicalIF":3.6000,"publicationDate":"2023-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/48/03/WJSC-15-385.PMC10277963.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of stem cells","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4252/wjsc.v15.i5.385","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL & TISSUE ENGINEERING","Score":null,"Total":0}

引用次数: 1

Abstract

Spinal cord injury (SCI) is a devastating condition with complex pathological mechanisms that lead to sensory, motor, and autonomic dysfunction below the site of injury. To date, no effective therapy is available for the treatment of SCI. Recently, bone marrow-derived mesenchymal stem cells (BMMSCs) have been considered to be the most promising source for cellular therapies following SCI. The objective of the present review is to summarize the most recent insights into the cellular and molecular mechanism using BMMSC therapy to treat SCI. In this work, we review the specific mechanism of BMMSCs in SCI repair mainly from the following aspects: Neuroprotection, axon sprouting and/or regeneration, myelin regeneration, inhibitory microenvironments, glial scar formation, immunomodulation, and angiogenesis. Additionally, we summarize the latest evidence on the application of BMMSCs in clinical trials and further discuss the challenges and future directions for stem cell therapy in SCI models.

Abstract Image

查看原文本刊更多论文

以骨髓间充质干细胞为重点的脊髓损伤细胞移植治疗:进展和挑战。

脊髓损伤(SCI)是一种具有复杂病理机制的破坏性疾病，可导致损伤部位以下的感觉、运动和自主神经功能障碍。到目前为止，还没有有效的治疗脊髓损伤的方法。最近，骨髓间充质干细胞(bmscs)被认为是脊髓损伤后最有希望的细胞治疗来源。本综述的目的是总结利用骨髓间充质干细胞治疗脊髓损伤的细胞和分子机制的最新见解。本文主要从神经保护、轴突萌发和/或再生、髓鞘再生、抑制微环境、胶质瘢痕形成、免疫调节和血管生成等方面综述了BMMSCs在脊髓损伤修复中的具体机制。此外，我们总结了BMMSCs在临床试验中应用的最新证据，并进一步讨论了干细胞治疗在SCI模型中的挑战和未来方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of stem cells Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

7.80

自引率

4.90%

发文量

750

期刊介绍： The World Journal of Stem Cells (WJSC) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of stem cells. It was launched on December 31, 2009 and is published monthly (12 issues annually) by BPG, the world''s leading professional clinical medical journal publishing company.